Elanix Biotechnologies AG (FRA:ELN) Change In Receivables : €0.00 Mil (TTM As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Change In Receivables?

Elanix Biotechnologies AG's change in receivables for the quarter that ended in Dec. 2018 was €0.00 Mil. It means Elanix Biotechnologies AG's Accounts Receivable stayed the same from Jun. 2018 to Dec. 2018 .

Elanix Biotechnologies AG's change in receivables for the fiscal year that ended in Dec. 2018 was €0.00 Mil. It means Elanix Biotechnologies AG's Accounts Receivable stayed the same from Dec. 2017 to Dec. 2018 .

Elanix Biotechnologies AG's Accounts Receivable for the quarter that ended in Dec. 2018 was €0.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Elanix Biotechnologies AG's Days Sales Outstanding for the six months ended in Dec. 2018 was 171.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Elanix Biotechnologies AG's liquidation value for the six months ended in Dec. 2018 was €-2.44 Mil.

Elanix Biotechnologies AG Change In Receivables Historical Data

The historical data trend for Elanix Biotechnologies AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Change In Receivables Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Receivables

Get a 7-Day Free Trial

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Elanix Biotechnologies AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Elanix Biotechnologies AG (FRA:ELN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Elanix Biotechnologies AG's Days Sales Outstanding for the quarter that ended in Dec. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.03	/	0.032	*	91
=	171.09

2. In Ben Graham's calculation of liquidation value, Elanix Biotechnologies AG's accounts receivable are only considered to be worth 75% of book value:

Elanix Biotechnologies AG's liquidation value for the quarter that ended in Dec. 2018 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.02	-	2.48	+	0.75 * 0.03	+	0.5 * 0
=	-2.44

Elanix Biotechnologies AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines